Skip to main content
PMC home page
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2015 Sep 15;8:2617–2625. doi: 10.2147/OTT.S91025

The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis

Baohua Huang 1,*, Lei Chen 1,*, Cuixia Bao 1, Chengming Sun 1, Jie Li 1, Lipeng Wang 1, Xia Zhang 1
PMCID: PMC4592050  PMID: 26451118

Abstract

Background

Programmed cell death 1 ligand 1 (PD-L1) expression has been observed in various malignancies. However, the association between PD-L1 expression and the survival of patients with gastrointestinal tract cancer remains controversial. Besides, the rate of PD-L1 positivity on tumor cells of digestive tract cancer is not clear. Thus, we performed a meta-analysis by incorporating all available evidence to evaluate the rate of PD-L1 positivity and the overall survival (OS) according to PD-L1 status in patients with gastrointestinal tract cancer.

Methods

Electronic databases were searched for eligible literature. Hazard ratios (HRs) for OS with 95% confidence intervals (CIs) according to the expression status of PD-L1 evaluated by immunohistochemistry were extracted. The outcomes were synthesized based on a random-effects model.

Results

Fifteen studies (only nine reported OS) that involved 2,993 gastrointestinal tract cancer patients stratified by PD-L1 status were eligible for inclusion in our study. We found the PD-L1-positive expression rate was 0.495 (95% CI 0.415–0.576) if 10% was taken as the cut-off value. When the H-score method was used to evaluate PD-L1 expression, it showed that the PD-L1 positive rate was 0.639 (95% CI 0.490–0.765) if the cut-off value was <50, which was higher than when using >50 as the cut-off point (0.449, 95% CI 0.417–0.483). Additionally, PD-L1-positive gastrointestinal tract cancer patients were associated with significantly poorer OS when compared to negative ones (HR 1.61, 95% CI 1.10–2.35, P=0.014). Subgroup analysis presented similar significant results in patients with esophageal cancer (HR 2.56, 95% CI 1.55–4.21, P<0.001).

Conclusion

The positive expression rate of PD-L1 was nearly 50% no matter which method for immunohistochemistry evaluation we chose. Additionally, positive PD-L1 expression status in tumor cells is a risk factor for prognosis of gastrointestinal tract cancer, especially esophageal cancer.

Keywords: prognosis, esophageal cancer, immunohistochemistry, PD-L1-positive expression rate

Introduction

Gastrointestinal tract cancer refers to malignant conditions of the gastrointestinal tract, including of the esophagus, stomach, small intestine, large intestine, rectum, and anus. Among those cancer patients, colorectal carcinoma, gastric cancer, and esophageal cancer are common types (the third, fourth, and sixth most-frequently diagnosed malignancies, respectively) globally.1–3 Although recent advances in multidisciplinary therapies have improved treatment outcomes, the overall prognosis for gastrointestinal tract cancer remains poor. It is well known that the development and prognosis of malignant tumors are closely related to host immune functions.4 Thus, novel therapeutic strategies, especially immunotherapy, are needed to be developed and established.4

It has been identified that immune escape plays an important role in tumor progression.5 Improved understanding of the molecular mechanisms that govern the host response to tumors has led to the identification of checkpoint signaling pathways that limit the anticancer immune response.6 A particularly important immune checkpoint that mediates tumor-induced immune suppression is the binding of programmed death 1 (PD-1) expressed on tumor-infiltrating lymphocytes and its ligand 1 (PD-L1) expressed on tumor cells.7 PD-L1 has been reported to inhibit the proliferation of activated T-cells and induce the apoptosis of T-cells to form and maintain an immunosuppressive microenvironment since PD-L1 can recognize and bind the PD-1 on tumor-infiltrating lymphocytes.8

PD-L1 expression has been observed in various malignancies. Moreover, several meta-analyses have proved that PD-L1 overexpression indicates a poor prognosis for patients with non-small cell lung cancer.9–11 However, the association between PD-L1 expression and the survival of patients with gastrointestinal tract cancer remains controversial. Besides, the rate of PD-L1 positivity on tumor cells of digestive tract cancer is not clear. Therefore, the expression status and prognostic significance of PD-L1 require further comprehensive study to clarify. Thus, we performed a meta-analysis by incorporating all available evidence to evaluate the expression rate of PD-L1 and the overall survival (OS) according to PD-L1 status in patients with gastrointestinal tract cancer.

Materials and methods

Literature search

Our institutions Ethics Committee has exempted our study from Institutional Review Board approval as our study involves exclusively preexisting anonymous data. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement for reporting systematic reviews recommended by the Cochrane Collaboration was followed for conducting this meta-analysis. Two authors independently carried out a comprehensive systematic search for published articles or abstracts by searching through PubMed, Embase, Scopus, and the Cochrane Library from inception to April 2015. Searches were limited to human studies, using a combination of the terms “PD-L1”, “CD274”, “B7-H1”, “programmed cell death 1 ligand 1”, “gastrointestinal”, “esophageal”, “gastric”, “colorectal”, “outcome”, “survival”, and “prognosis”. We also manually reviewed relevant reference lists and reviews. There were no language restrictions.

Inclusion and exclusion criteria

Studies meeting the following criteria were eligible for the single-arm meta-analysis of PD-L1-positive expression rate on tumor cells: (1) cohort studies which investigated PD-L1 expression level in gastrointestinal tract cancer patients; (2) the expression level of PD-L1 was tested by immunohistochemistry (IHC) staining in the tissue specimens; (3) samples of PD-L1 positive and PD-L1 negative were available. Moreover, studies in the meta-analysis that focused on patients’ survival according to PD-L1 status met the following criteria: (1) studies meeting the criteria of meta-analysis for PD-L1-positive expression rate; (2) survival data stratified by PD-L1 status was available. Studies that failed to meet the inclusion criteria were excluded.

Outcome measures, data extraction, and quality assessment

The primary outcome for this meta-analysis was PD-L1-positive expression rate and OS. OS data were extracted in the form of hazard ratios (HRs) with the corresponding 95% confidence interval (CI). If the HR was not displayed directly, it was estimated according to the methods described by a previously published article.12 The data collection and assessment of methodological quality followed the quality of reporting of meta-analyses (QUORUM) and the Cochrane Collaboration guidelines (http://www.cochrane.de). The following main items were abstracted from the included studies: author, year, tumor type, IHC evaluation method and cut-off value, sample size of total patients and PD-L1-positive group, and survival data. Two reviewers used the modified Newcastle–Ottawa scale to assess these studies.13 All investigators discussed and resolved all discrepancies in the extracted data. All of the eligible studies were of high quality.

Statistical analysis

All calculations for PD-L1-positive expression rate on tumor cells were performed using Meta-Analyst Beta (v 3.13; Tufts Medical Center, Boston, MA, USA). HRs for OS with 95% CIs according to the expression status of PD-L1 was pooled using STATA (v 11.0; StataCorp, College Station, TX, USA). Heterogeneity across the incorporated studies was assessed with a forest plot and the inconsistency statistic (I2). A random-effects model was employed in case of potential heterogeneity and to avoid underestimation of standard errors of pooled estimates in this meta-analysis. Subgroup analysis was conducted according to IHC evaluation method and cut-off value and tumor type. An HR that was greater than 1 reflected shorter OS for PD-L1-positive patients. All CIs had two-sided probability coverage of 95%. A statistical test with a P-value less than 0.05 was considered as significant.

Publication bias

An extensive search strategy was made to minimize the potential publication bias. Graphical funnel plots were generated to visually assess publication bias. The statistical method to detect funnel plot asymmetry was Begg’s test.14

Results

Eligible studies

In total, 574 records were identified according to the search strategy. Finally, we enrolled 15 studies15–29 that involved 2,993 gastrointestinal tract cancer patients (1,461/1,532 cases for PD-L1 positive/negative) with available PD-L1 expression data stratified by PD-L1 status. Nine of the studies16–19,21,23,26–28 reported HRs for OS as a clinical outcome. Figure 1 summarizes the flow chart of study selection. Our study covered three major types of gastrointestinal tract cancer, esophageal cancer, gastric cancer, and colorectal carcinoma. The H-score was one of the most common methods used to evaluate the expression of PD-L1 in the tumor cells among the included articles, as well as the percentage of positively stained cells. The characteristics of the enrolled studies are shown in Table 1.

Figure 1.

Figure 1

Open in a new tab

Flow chart of study selection.

Abbreviation: PD-L1, programmed cell death 1 ligand 1.

Table 1.

Characteristics of included studies for meta-analyses

Study, year Tumor type IHC evaluationa Cut-off value for PD-L1 (+) Patients, N Age ≥60 years (%) Male, n (%) Country PD-L1 (+) patients (%) HRb for OS Lower limit of 95% CI Upper limit of 95% CI
Ohigashi et al15, 2005 EC Percentage ≥10% 31 NA NA Japan 13 (41.94) NA NA NA
Loos et al16, 2011 EC H-score ≥66 101 NA NA Germany 37 (36.63) 2.92 1.5 5.66
Chen et al17, 2014 EC H-score >0 99 48 (48.48) 76 (76.77) People’s Republic of China 82 (82.83) 2.157 1.017 4.577
Wu et al18, 2006 GC NA NA 102 64 (62.75) 75 (73.53) People’s Republic of China 43 (42.16) 2.74 1.23 6.1
Geng et al19, 2014 GC H-score ≥22 100 65 (65.00) 61 (61.00) People’s Republic of China 65 (65.00) 1.65 1.16 2.73
Hou et al20, 2014 GC Percentage ≥10% 111 56 (50.45)* 75 (67.57) People’s Republic of China 70 (63.06) NA NA NA
Kim et al21, 2014 GC Percentage ≥10% 243 53 (21.81)# 152 (62.55) Korea 106 (43.62) 0.651 0.416 1.017
Jiang et al22, 2014 GC H-score ≥60 205 128 (62.44) 151 (73.66) People’s Republic of China 88 (42.93) NA NA NA
Qing et al23, 2015 GC Percentage ≥10% 107 62 (57.94) 72 (67.29) People’s Republic of China 54 (50.47) 1.649 1.173 2.318
Hua et al24, 2012 CRC H-score ≥200 33 NA NA People’s Republic of China 15 (45.45) NA NA NA
Zhang et al25, 2012 CRC Percentage ≥10% 57 36 (63.16) 35 (61.40) People’s Republic of China 26 (45.61) NA NA NA
Droeser et al26, 2013 CRC H-score ≥200 1,420 NA 673 (47.6) Switzerland 669 (47.11) 0.85 0.81 0.89
Shi et al27, 2013 CRC H-score ≥200 143 69 (48.25) 61 (42.66) People’s Republic of China 64 (44.76) 2.611 1.008 3.576
Liang et al28, 2014 CRC H-score ≥20 185 114 (61.62) 87 (47.03) People’s Republic of China 102 (55.14) 1.74 1.195 2.713
Zhao et al29, 2014 CRC H-score ≥20 56 30 (53.57) 35 (62.50) People’s Republic of China 27 (48.21) NA NA NA
Open in a new tab

Notes:

a

H-score = SI (staining intensity) × PP (percentage of positive cells). SI was determined as: 0, negative; 1, weak; 2, moderate; and 3, strong. PP was defined as: 0, negative; 1–100, 1–100% positive cells.

*

Age ≥58 years;

#

age ≥/>70 years.

b

HR represents HR PD-L1 positive/PD-L1 negative.

Abbreviations: CI, confidence interval; CRC, colorectal cancer; EC, esophageal cancer; GC, gastric carcinoma; HR, hazard ratio; IHC, immunohistochemistry; NA, not available; OS, overall survival; PD-L1, programmed cell death 1 ligand 1; PD-L1 (+), PD-L1 positive.

Single-arm meta-analysis of positive expression rate of PD-L1

After stratifying the enrolled studies according to IHC evaluation method and cut-off value, we found the PD-L1-positive expression rate was 0.495 (95% CI 0.415–0.576) if 10% was taken as the cut-off value. When the H-score method was used to evaluate PD-L1 expression, it showed that the PD-L1 positive rate was 0.639 (95% CI 0.490–0.765) if the cut-off value was <50, which was higher than when >50 was used as the cut-off point (0.449, 95% CI 0.417–0.483) (Figure 2).

Figure 2.

Figure 2

Figure 2

Open in a new tab

Single-arm meta-analysis of positive expression rate of programmed cell death 1 ligand 1 (PD-L1) on tumor cells in gastrointestinal tract cancer according to immunohistochemistry evaluation method and cut-off value.

Notes: (A) Percentage (cut-off value 10%); (B) H-score (cut-off value <50); (C) H-score (cut-off value >50).

Meta-analysis of PD-L1 positive versus PD-L1 negative in terms of OS

Overall, positive expression of PD-L1 in the tumor cells of gastrointestinal tract cancer patients was associated with a significantly poorer OS than negative expression (HR 1.61, 95% CI 1.10–2.35, P=0.014) (Figure 3).

Figure 3.

Figure 3

Open in a new tab

Total meta-analysis of programmed cell death 1 ligand 1 (PD-L1) positive versus PD-L1 negative on tumor cells of gastrointestinal tract cancer patients in terms of overall survival.

Note: Weights are from random-effects analysis.

Abbreviations: CI, confidence interval; HR, hazard ratio.

Subgroup analyses, sensitivity analyses, and publication bias

The H-score evaluation method showed inferior survival in the PD-L1-positive group if we took <50 as the cutoff value (HR 1.75, 95% CI 1.33–2.31, P<0.001). The results were similar when using >50 as the cut-off value (HR 1.79, 95% CI 0.69–4.62, P=0.231). However, an only slightly numerical adverse prognostic effect of PD-L1-positive expression was presented if 10% was taken as the cut-off value using the percentage method (HR 1.05, 95% CI 0.42–2.61, P=0.919) (Figure 4). Additionally, when stratifying studies according to tumor type, we observed that meta-analysis presented significant poorer OS in the PD-L1-positive group of patients with esophageal cancer (HR 2.56, 95% CI 1.55–4.21, P<0.001). Similar numerical survival benefits were found in the PD-L1 negative groups of patients with gastric cancer (HR 1.42, 95% CI 0.84–2.41, P=0.194) and colorectal carcinoma (HR 1.49, 95% CI 0.74–3.00, P=0.260) (Figure 4). Funnel plots with Begg’s test are shown in Figure S1.

Figure 4.

Figure 4

Open in a new tab

Subgroup analysis of programmed cell death 1 ligand 1 (PD-L1) positive versus PD-L1 negative on tumor cells of gastrointestinal tract cancer patients in terms of overall survival.

Note: Weights are from random-effects analysis.

Abbreviations: CI, confidence interval; HR, hazard ratio; IHC, immunohistochemistry.

Discussion

For patients with gastrointestinal tract malignancies, the association of the expression of PD-L1 and their prognosis remains unclear. In addition, the positive expression rate of PD-L1 in the tumor cells of digestive tract cancer is still unknown. A meta-analysis incorporating all available data from correlative studies is a reasonable method by which to address these questions. We conducted this study and found nearly 50% of gastrointestinal tract cancer patients showed positive expression of PD-L1. Furthermore, patients with positive expression of PD-L1 had significantly poorer survival than with those with negative expression.

It is notable that the PD-L1 expression rate was delineated less when stricter criteria for positive PD-L1 expression were applied. We could see that studies using a cut-off value >50 for H-score16,22,24,26,27 showed a lower positive PD-L1 expression rate than those using <50.17,19,28,29 A similar result was found if 10% was taken as the cut-off value when using the percentage method. Since IHC evaluation methods and cut-off values were not consistent for each gastrointestinal tract cancer type, subgroup meta-analysis was not possible when studies were stratified by tumor type. We could also see that studies using a cut-off value >50 for H-score16,26,27 showed a greater difference in OS between PD-L1 positive and negative groups than those using <50,17,19,28 although no significant survival benefits were obtained in the former due to limited sample sizes. Moreover, the unfavorable prognostic value of PD-L1 was significantly seen in patients with esophageal cancer.16,17 Despite some trends observed, we currently cannot draw a valid conclusion that PD-L1 status is a predictor of prognosis for patients with gastric cancer or colorectal carcinoma. Considering the consistent trend of the prognostic significance of PD-L1 when using different kinds of anti-PD-L1 antibodies to stain tumor cells has been proven in another meta-analysis,30 subgroup analyses regarding source and type of antibody are not necessary.

Limitations and future directions

Efforts were made to conduct a comprehensive analysis to answer the question of expression rate of PD-L1 and the impact of PD-L1 status on patient prognosis in gastrointestinal tract cancer, but some limitations still should be acknowledged. First of all, we calculated or estimated some survival data of the HRs from the available data or Kaplan–Meier curves, which may have compromised the precision of the data. Secondly, cut-off values distinguishing positive and negative expression of PD-L1 determined by IHC evaluation and the primary antibodies varied in different types of tumors, which might cause heterogeneity of the overall results. The subgroup results should have addressed some concerns. Thirdly, we were not able to evaluate the expression rate of PD-L1 stratified by tumor type in subgroup analysis due to inconsistent IHC evaluations. Fourthly, we were unable to determine whether a correlation exists between positive PD-L1 expression and the clinical characteristics of gastrointestinal tract cancer. In addition, most of the eligible studies failed to provide data regarding progression-free survival or recurrence-free survival, so we only extracted OS data in our meta-analysis. Besides, scientists might prefer to only report the positive results of a prognostic biomarker, leading to the existence of potential publication bias. Further studies are warranted to address the above issues.

Regardless of the described limitations, this comprehensive analysis statistically confirmed almost half of all gastrointestinal tract cancer patients positively expressed PD-L1 in tumor cells and those PD-L1 positive patients were associated with significantly shorter OS, especially in esophageal cancer. A recent study has confirmed that positive PD-L1 expression is correlated with the improved efficacy of pembrolizumab, a drug marketed by Merck that targets the PD-1 receptor, in patients with advanced non-small-cell lung cancer.31 These results hint that, in clinical trials using anti-PD-L1 or anti-PD-1 antibodies as cancer immunotherapy, enrollment might also be preferentially carried out on patients with gastrointestinal tract cancer, especially esophageal cancer. Furthermore, more efforts should be made to investigate which cut-off value is the best for differentiating real PD-L1-positive patients with gastrointestinal tract cancer who would get survival benefit from PD-1/PD-L1 blockers.

Conclusion

In this meta-analysis, we found the positive expression rate of PD-L1 was nearly 50%, no matter which method for IHC evaluation we chose. Additionally, we found positive PD-L1 expression status in tumor cells is a risk factor for prognosis in gastrointestinal tract cancer, especially in esophageal cancer.

Supplementary materials

Figure S1

Graphical funnel plots with Begg’s test of the meta-analysis.

Abbreviations: HR, hazard ratio; SE, standard error.

ott-8-2617s1.tif (106.3KB, tif)

Acknowledgments

This study was supported by the National Natural Science Foundation of China (number 81202069).

The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of this paper.

Footnotes

Disclosure

The authors declare no conflicts of interest in this work.

References

  • 1.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi: 10.3322/caac.20138. [DOI] [PubMed] [Google Scholar]
  • 2.Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev. 2008;3:CD004183. doi: 10.1002/14651858.CD004183.pub3. [DOI] [PubMed] [Google Scholar]
  • 3.Yang S, Wu S, Huang Y, et al. Screening for oesophageal cancer. Cochrane Database Syst Rev. 2012;12:CD007883. doi: 10.1002/14651858.CD007883.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol. 2015;6(2):208–223. doi: 10.3978/j.issn.2078-6891.2014.077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am. 2007;16(4):755–774. doi: 10.1016/j.soc.2007.08.004. [DOI] [PubMed] [Google Scholar]
  • 6.Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297–339. doi: 10.1016/S0065-2776(06)90008-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662–673. doi: 10.1002/cam4.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chen J, Li G, Meng H, et al. Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother. 2012;61(1):101–108. doi: 10.1007/s00262-011-1094-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wang A, Wang HY, Liu Y, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. 2015;41(4):450–456. doi: 10.1016/j.ejso.2015.01.020. [DOI] [PubMed] [Google Scholar]
  • 10.Zhou ZJ, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4(2):203–208. doi: 10.3978/j.issn.2218-6751.2015.03.02. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2015;7(3):462–470. doi: 10.3978/j.issn.2072-1439.2015.02.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses [research tool] Ottawa, ON: Ottawa Hospital Research Institute; 2014. [Accessed August 1, 2015]. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. [Google Scholar]
  • 14.Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. [PubMed] [Google Scholar]
  • 15.Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11(8):2947–2953. doi: 10.1158/1078-0432.CCR-04-1469. [DOI] [PubMed] [Google Scholar]
  • 16.Loos M, Langer R, Schuster T, et al. Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma. Ann Thorac Surg. 2011;91(4):1025–1031. doi: 10.1016/j.athoracsur.2010.12.041. [DOI] [PubMed] [Google Scholar]
  • 17.Chen L, Deng H, Lu M, et al. B7-H1 expression associates with tumor invasion and predicts patient’s survival in human esophageal cancer. Int J Clin Exp Pathol. 2014;7:6015–6023. [PMC free article] [PubMed] [Google Scholar]
  • 18.Wu C, Zhu Y, Jiang J, et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108(1):19–24. doi: 10.1016/j.acthis.2006.01.003. [DOI] [PubMed] [Google Scholar]
  • 19.Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol. 2014;20(2):273–281. doi: 10.1007/s10147-014-0701-7. [DOI] [PubMed] [Google Scholar]
  • 20.Hou J, Yu Z, Xiang R, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol. 2014;96(3):284–291. doi: 10.1016/j.yexmp.2014.03.005. [DOI] [PubMed] [Google Scholar]
  • 21.Kim JW, Nam KH, Ahn SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 2014 Nov 26; doi: 10.1007/s10120-014-0440-5. Epub. [DOI] [PubMed] [Google Scholar]
  • 22.Jiang D, Xu YY, Li F, Xu B, Zhang XG. The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism. Med Oncol. 2014;31(11):268. doi: 10.1007/s12032-014-0268-1. [DOI] [PubMed] [Google Scholar]
  • 23.Qing Y, Li Q, Ren T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015;9:901–909. doi: 10.2147/DDDT.S75152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hua D, Sun J, Mao Y, Chen LJ, Wu YY, Zhang XG. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World J Gastroenterol. 2012;18(9):971–978. doi: 10.3748/wjg.v18.i9.971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Zhang MY, Yang YY, Wang XH, Li XF. Expression of Bcl-2, PD-L1 and its clinical significance in colorectal cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012;43(6):827–829. 859. Chinese. [PubMed] [Google Scholar]
  • 26.Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer. 2013;49(9):2233–2242. doi: 10.1016/j.ejca.2013.02.015. [DOI] [PubMed] [Google Scholar]
  • 27.Shi SJ, Wang LJ, Wang GD, et al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One. 2013;8(10):e76012. doi: 10.1371/journal.pone.0076012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Liang M, Li J, Wang D, et al. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China’s Heilongjiang province. Tumor Biol. 2014;35(1):55–60. doi: 10.1007/s13277-013-1006-6. [DOI] [PubMed] [Google Scholar]
  • 29.Zhao LW, Li C, Zhang RL, et al. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem. 2014;116(7):1163–1168. doi: 10.1016/j.acthis.2014.06.003. [DOI] [PubMed] [Google Scholar]
  • 30.Zhang Y, Kang S, Shen J, et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) 2015;94(6):e515. doi: 10.1097/MD.0000000000000515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Garon EB, Rizvi NA, Hui R, et al. KEYNOTE-001 Investigators Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028. doi: 10.1056/NEJMoa1501824. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1

Graphical funnel plots with Begg’s test of the meta-analysis.

Abbreviations: HR, hazard ratio; SE, standard error.

ott-8-2617s1.tif (106.3KB, tif)

Articles from OncoTargets and therapy are provided here courtesy of Dove Press

RESOURCES